Personalized multi-assay profiling of respiratory motile ciliopathies and mRNA therapy
Georgia N. Ithakisiou, Pim CleijpooliD, Henriette H. M. RaeveniD, Bram M. BoschiD, Wessel Hornman, Daniëlle Hoenselaar, Marinos Tziouvelis, Aranka Gerritsen, Matthew B. SmithiD, Loes A. OosterhoffiD, R.B. Bhattacharjee, Zechen Wang, T. Noelle LombanaiD, Brandon A. Wustman, Cornelis Korstiaan van der EntiD, Karin M. de Winter‐de GrootiD, Sam F.B. van BeuningeniD, Eric Gerardus HaarmaniD, Tamara Paff, Jeffrey Matthijn BeekmaniD, Gimano D. AmatngalimiD, Bahar Yetkin-ArikiD
Abstract
IntroductionImpaired motile cilia function contributes to many respiratory disorders, but therapies targeting this cellular defect are currently lacking. Personalized airway epithelial models combined with quantitative, complementary ciliary assays can pave the way for the development of such therapies. However, existing airway epithelial cultures often show variable ciliogenesis, and ciliary function is frequently assessed using a single assay that does not capture the phenotypic heterogeneity of ciliary dysfunction. Here, we established a personalized, multi-assay in vitro platform using human nasal epithelial cells (HNECs) to assess ciliary function and therapeutic response, using primary ciliary dyskinesia (PCD) as a model disease. MethodsHNECs from 8 healthy individuals and 13 individuals with PCD carrying distinct disease-associated variants were obtained by nasal brushing. Cells were differentiated under optimized conditions, including {gamma}-secretase/Notch and BMP pathway inhibitors and a low liquid-liquid interface, to generate highly ciliated 2D epithelial cultures. Ciliary function was assessed using ciliary beat frequency, bead transport, and apical-out nasal organoid rotation assays. Therapeutic rescue was assessed in HNECs harboring DNAI1 alterations using DNAI1 mRNA-loaded lipid nanoparticles. ResultsOptimized differentiation yielded reproducibly multiciliated HNEC cultures. The multi-assay platform distinguished healthy from PCD-derived HNECs and revealed individual- and genotype-specific patterns of ciliary dysfunction not captured by a single assay. Basolateral administration of DNAI1 mRNA-loaded lipid nanoparticles resulted in partial, dose-dependent recovery of ciliary function in DNAI1-deficient HNECs. ConclusionThis study establishes a standardized, individual-specific multi-assay nasal epithelial platform for functional phenotyping of motile cilia and preclinical evaluation of emerging therapies, with demonstrated utility in PCD.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeted mRNA restoration of ciliary function in DNAI1-related primary ciliary dyskinesia: ex vivo rescue in patient-derived nasal spheroids, A pilot study
Caroline Marie Torp Nygaard, Cristian Herrera-Cid, … June Kehlet Marthin·bioRxiv·May 28, 2026
- Defining Functional Correction Thresholds in Primary Ciliary Dyskinesia for Effective Gene Therapies
Beck E. Fitzpatrick, Brett J. Wineinger, … Amy L. Ryan·bioRxiv·Feb 20, 2026
- Primary Ciliary Dyskinesia patient specific hiPSC-derived airway epithelium in Air Liquid Interface culture recapitulates disease specific phenotypes in vitro
L. von Schledorn, D. P. Martin, … R. Olmer·bioRxiv·Apr 25, 2023
- High-content screening for rare respiratory diseases: readthrough therapy in primary ciliary dyskinesia
D. D. H. Lee, D. Cardinale, … C. O'Callaghan·bioRxiv·Feb 28, 2020
- Ventral anterior foregut endoderm cells as progenitors for airway epithelial cell replacement in primary ciliary dyskinesia
Carine Bourdais, Agathe Coeur, … John De Vos·bioRxiv·Feb 8, 2026
- Development and Initial Characterization of Pigs with DNAI1 Mutations and Primary Ciliary Dyskinesia
Mahmoud H. Abou Alaiwa, Brieanna M. Hilkin, … David Anthony Stoltz·bioRxiv·May 22, 2024